Deals & Cases

Schellenberg Wittmer successfully represented Actavis in patent litigation against Eli Lilly


Actavis, an affiliate of Teva Pharmaceutical Industries, one of the leading pharmaceutical companies worldwide, was successfully represented in a patent litigation by Schellenberg Wittmer’s IP Team (lead counsel Andrea Mondini) against Eli Lilly.

After having dismissed Eli Lilly's request for preliminary injunctions, the Swiss Federal Patent Court granted Actavis a declaratory judgment on the merits that Actavis' pemetrexed diacid product does not infringe Eli Lilly's patent EP 1 313 508 B1 claiming pemetrexed disodium for cancer treatment. This patent is heavily litigated in several countries, including Germany and the United Kingdom.


Stay up to date!

*Required fields

Newsletters & Newsflashes

Monthly selected key topics from our practice areas, sectors and industries, plus newsflashes on recent developments.


Monthly email with the latest updates and summaries of the Swiss Federal Supreme Court's case law in arbitration matters.
Regular insights into Swiss and international trends and legal developments in the construction industry.
Regular insights and updates on key developments in the rapidly changing landscape of Environmental, Social and Corporate Governance disputes.
Concise analysis of key trends in the fast-moving world of corporate governance for board members of Swiss companies.
A regular look from a unique M&A perspective at legal changes, economic developments and societal trends in Switzerland.

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.